Then, we treated renal cancer cells with doxorubicin or both doxorubicin and miR‐34 inhibitors, and we found that miR‐34a inhibitors rescued the ability of doxorubicin to upregulate DAPK protein. The gene discussed is DAPK1; the disease is renal carcinoma.